Precision Diagnostics & Medicine Market by Diagnostic Testing, Diagnostics Indication, Therapeutic Products, Indication - Global Forecast to 2029
세계 정밀진단 및 정밀의료 시장 규모는 예측 기간 동안 11.1%의 CAGR로 확대되어 2024년 1,455억 3,000만 달러에서 2029년 2,466억 6,000만 달러에 달할 것으로 예상됩니다.
정밀의료 개발을 강화하기 위해 인공지능, 머신러닝 등 첨단 기술의 통합이 진행되고 있으며, 더 나은 정밀의료 솔루션을 개발하기 위해 대형 제약사 및 진단 의약품 업체들의 협력과 투자가 활발히 이루어지고 있다는 점이 시장 성장을 뒷받침하고 있습니다. 또한, 이들 기업이 신경퇴행성 질환, 자가면역질환 등 여러 질환에 대한 정밀 치료 및 진단 검사 개발에 집중하고 있는 것은 헬스케어에서 정밀의료의 중요성이 증가하고 있음을 보여줍니다. 또한, 환자들의 건강에 대한 인식이 높아지면서 웨어러블 의료기기와 소비자 직접 판매 정밀진단 검사의 채택이 증가하고 있으며, 이는 이 시장에 진입하는 기업들에게 성장 기회를 제공하고 있습니다. 그러나 정밀의료의 높은 비용과 헬스케어 빅데이터의 통합 및 관리와 관련된 과제는 이 시장의 성장을 저해할 것으로 예상됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2022-2029년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(달러) |
| 부문별 |
유형별, 적응증별, 제품별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
2023년 단클론항체 부문은 제품별 정밀의료 시장 내에서 가장 높은 성장률을 기록했습니다. 첨단 단클론항체 개발을 위한 공동 연구 증가와 항체 공학 기술의 발전 등의 요인이 이 부문의 성장에 기여하고 있습니다. 또한, 이러한 치료법은 기존 약물에 비해 높은 특이성, 낮은 독성, 더 오래 지속되는 효과 등 다양한 이점을 제공하기 때문에 암, 자가면역질환, 감염성 질환의 치료에 이러한 치료법의 채택이 증가하고 있으며, 이는 이 부문의 성장을 뒷받침하고 있습니다.
병원 및 클리닉 최종사용자는 예측 기간 동안 최종사용자별 정밀의료 시장에서 가장 높은 성장률을 기록했습니다. 맞춤형 치료에 대한 수요 증가와 병원 및 클리닉이 통제된 환경에서 맞춤형 치료를 제공할 수 있는 능력 등이 이 최종사용자 부문의 높은 점유율을 견인하는 요인으로 작용하고 있습니다. 또한, 병원과 제약 및 진단 기업과의 협력을 통해 맞춤형 치료 및 진단 테스트를 개발하기 위해 병원과 제약 및 진단 기업 간의 협력 관계가 증가하고 있는 것도 이 부문의 성장을 뒷받침하고 있습니다. 병원과 클리닉은 고급 정밀 솔루션 개발을 위해 이들 기관으로부터 실제 데이터를 수집하는 기업들에게 데이터 저장소 역할을 합니다. 이러한 높은 성장세는 예측 기간 동안 지속될 것으로 예상됩니다.
아시아태평양의 정밀진단 시장은 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예상됩니다. 이러한 높은 성장은 이 지역의 만성질환, 암, 유전성 질환의 증가와 정밀진단 솔루션에 대한 수요 증가에 기인합니다. 이러한 성장은 중국, 인도, 일본과 같은 국가들의 의료 인프라에 대한 투자로 첨단 진단 기술에 대한 접근성이 강화되면서 뒷받침되고 있습니다. 또한, 차세대 염기서열 분석(NGS), 인공지능, 머신러닝과 같은 기술의 채택이 이 분야의 기술 혁신을 촉진하고 있습니다. 정부의 노력과 의료 보장 개선도 정밀진단에 대한 접근성 확대에 기여하고 있습니다. 또한, 생명과학 연구개발에 대한 정부 기관의 지원과 자금 지원도 아시아태평양의 정밀진단 시장의 빠른 성장을 뒷받침하고 있습니다.
세계의 정밀진단 및 정밀의료 시장에 대해 조사했으며, 유형별, 적응증별, 제품별, 최종사용자별, 지역별 동향, 시장 진입 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 소개
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
- 소개
- 시장 역학
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 생태계 분석
- 파이프라인 분석
- 진단 제품 분석
- 투자/자금 조달 활동
- 기술 분석
- 특허 분석
- 무역 분석
- 2025-2026년의 주요 회의와 이벤트
- 규제 상황
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- AI/생성형 AI가 정밀진단 및 정밀의료 시장에 미치는 영향
제6장 정밀진단 시장, 유형별
제7장 정밀진단 시장, 적응증별
제8장 정밀진단 시장, 최종사용자별
제9장 정밀의료 시장, 제품별
- 소개
- 단클론항체
- 억제제
- 세포 및 유전자 치료
- 항바이러스제 및 항레트로바이러스제
- 기타
제10장 정밀의료 시장, 적응증별
제11장 정밀의료 시장, 최종사용자별
제12장 정밀진단 및 정밀의료 시장, 지역별
- 소개
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
제13장 경쟁 구도
- 개요
- 주요 진출 기업 전략/강점, 2021-2024년
- 매출 분석, 2021-2023년
- 시장 점유율 분석, 2023년
- 기업 평가 매트릭스 : 주요 진출 기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 가치 평가와 재무 지표
- 브랜드/제품 비교
- 정밀진단 시장 : 경쟁 시나리오
- 정밀의료 시장 : 경쟁 시나리오
제14장 기업 개요
- 주요 진출 기업
- F. HOFFMANN-LA ROCHE LTD(DIAGNOSTICS)
- ABBOTT
- AGILENT TECHNOLOGIES, INC.
- GUARDANT HEALTH
- EXACT SCIENCES CORPORATION
- QIAGEN
- MYRIAD GENETICS, INC.
- NATERA, INC.
- ILLUMINA, INC.
- THERMO FISHER SCIENTIFIC INC.
- DANAHER
- 23ANDME, INC.
- MERCK & CO., INC.
- GILEAD SCIENCES, INC.
- F. HOFFMANN-LA ROCHE LTD(MEDICINE)
- BRISTOL-MYERS SQUIBB COMPANY
- NOVARTIS AG
- ASTRAZENECA
- ABBVIE INC.
- LILLY
- PFIZER INC.
- SAREPTA THERAPEUTICS, INC.
- VERTEX PHARMACEUTICALS INCORPORATED
- GSK PLC.
- 기타 기업
- SANOFI
- JOHNSON & JOHNSON SERVICES, INC.
- AMGEN INC.
- MERCK KGAA
- ALNYLAM PHARMACEUTICALS, INC.
- INCYTE
- ARUP LABORATORIES
- DEVYSER
- DIASORIN S.P.A.
- TEMPUS
- PILLAR BIOSCIENCES INC.
- INVIVOSCRIBE, INC.
- NEUROCODE
- C2N DIAGNOSTICS
- TRINITY BIOTECH
- AMOY DIAGNOSTICS CO., LTD.
제15장 부록
ksm
The global Precision Diagnostics and Medicine market is projected to reach USD 246.66 billion in 2029 from USD 145.53 billion by 2024, at a CAGR of 11.1% during the forecast period. Factors such as the ongoing integration of advanced technologies such as artificial intelligence and machine learning to enhance precision medicine development, supported by the rising collaboration and investments by major pharmaceutical and diagnostics companies to develop better precision medicine solutions are supporting the growth of the market. Moreover, the expanding focus of these companies to develop precision therapies and diagnostic tests for multiple diseases such as neurodegenerative and autoimmune diseases highlight the growing importance of precision medicine in healthcare. Additionally, the increasing awareness of patients regarding their health is supporting the adoption of wearable medical devices and direct-to-consumer precision diagnostic tests offering growth opportunities to players in this market. However, the high cost of precision healthcare and challenges associated with the integration and management of big data in healthcare are expected to restrain the growth of this market.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Diagnostic Solution Type, Diagnostic Solution Indication, Diagnostic Solution End Users, Therapeutic Solution Products |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The monoclonal antibodies segment registered the highest growth rate in the precision medicine market, by products, during the forecast period"
In 2023, the monoclonal antibodies segment registered the highest growth rate within the precision medicine market by products. Factors such as the increasing collaborations to develop advanced monoclonal antibodies and advancements in antibody engineering technologies are attributed to the growth of this segment. Additionally, these modalities offer various advantages over traditional drugs such as high specificity, low toxicity, and longer-lasting effects among others increasing the adoption of these drug modalities for the treatment of cancer, autoimmune, and infectious diseases supporting the growth of this segment.
"The hospitals and clinics end user segment registered the highest growth rate and largest market share in the precision medicine market, by end user, during the forecast period"
The hospitals and clinic end users registered the highest growth rate within the precision medicine market by end user segment during the forecast period. Factors such as the growing demand for personalized treatments and the ability of hospitals and clinics to offer personalized therapies in a controlled environment can be attributed to the large share of this end user segment. Moreover, the rising collaborations between hospitals and pharmaceutical and diagnostic companies to develop personalized therapies and diagnostic tests support the growth of this segment. Hospitals and clinics act as data reservoirs for these companies which gather real-world data from these institutions for the development of advanced precision solutions. This high growth is projected to continue during the forecast period.
"Asia Pacific: The fastest growing region in the Precision Diagnostics market"
The precision diagnostics market of Asia Pacific is projected to register the highest growth rate during the forecast period. This high growth is attributed to the rising cases of chronic diseases, cancer, and genetic disorders in this region leading to a growing demand for precision diagnostics solutions. This growth is supported by investments in healthcare infrastructure across countries like China, India, and Japan, enhancing access to advanced diagnostic technologies. Additionally, the adoption of technologies like next-generation sequencing (NGS), artificial intelligence, and machine learning is driving innovations in the field. Government initiatives and improved healthcare coverage also contribute to expanding access to precision diagnostics. Moreover, the support and funding from government organizations for life sciences research and development also support the rapid growth of the Asia Pacific precision diagnostics market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 44%, Tier 2 - 32%, and Tier 3 - 24%
- By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, ROW -15%
List of Companies Profiled in the Report:
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Myriad Genetics, Inc. (US)
- Guardant Health (US)
- Abbott (US)
- Natera Inc. (US)
- Illumina, Inc. (US)
- Danaher (US)
- Exact Sciences Corporation (US)
- Qiagen (Netherlands)
- 23andME, INC. (US)
- ARUP Laboratories. (US)
- Devyser (Sweden)
- Diasorin S.P.A. (Italy)
- Tempus (US)
- Pillar Biosciences Inc. (US)
- Invivoscribe, Inc. (US)
- NeuroCode (US)
- C2N Diagnostics (US)
- Trinity Biotech Plc. (Ireland)
- Amoy Diagnostics Co., Ltd. (China)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (US)
- Gilead Sciences, Inc. (US)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Eli Lilly and Company. (US)
- Pfizer Inc. (US), GSK plc. (UK)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (US)
- Vertex Pharmaceuticals Incorporated (US)
- Amgen Inc. (US)
- Merck KGaA (Germany)
- Sarepta Therapeutics, Inc. (US).
Research Coverage:
This report provides a detailed picture of the global Precision Diagnostics and Medicine Market. It aims to estimate the size and future growth potential of the market across different segments such as the precision diagnostics market (type, indication, and end user) and precision medicine market (product, indication, and end user) region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the precision diagnostics and medicine market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the precision diagnostics and medicine market. Competitive analysis of upcoming startups in the precision diagnostics and medicine market ecosystem is covered in this report.
Reasons to buy this report :
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall precision diagnostics and medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing Integration Of AI And ML To Improve Precision Diagnostics And Therapy Development, Rising Collaborations Between Pharmaceutical And Diagnostics Company To Enhance Precision Healthcare and Rise in direct-to-consumer testing), restraints (High costs of precision healthcare and Slow Pace Of Reimbursement For Precision Diagnostics), opportunities (Expanding The Application Of Precision Diagnostics From Oncology and Integration of wearable devices to enhance precision healthcare), and challenges (Challenges in Regulatory Approval for Diagnostics and Big Data Management and Integration) influencing the growth of the precision diagnostics and medicine market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches and approvals in the precision diagnostics and medicine market
- Market Development: Comprehensive information about lucrative markets - the report analyses the precision diagnostics and medicine market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the precision diagnostics and medicine market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players in precision diagnostics market like- F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Guardant Health (US), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US) among others and precision medicine market like- Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US) Gilead Sciences, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Novartis AG (Switzerland), among others.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION METHODOLOGY
- 2.2.1 PRECISION DIAGNOSTICS MARKET
- 2.2.2 PRECISION MEDICINE MARKET
- 2.2.3 INSIGHTS FROM PRIMARY SOURCES
- 2.3 TOP-DOWN APPROACH
- 2.3.1 PRECISION DIAGNOSTICS MARKET
- 2.3.2 PRECISION MEDICINE MARKET
- 2.4 GROWTH FORECAST MODEL
- 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.8 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PRECISION DIAGNOSTICS MARKET OVERVIEW
- 4.2 PRECISION MEDICINE MARKET OVERVIEW
- 4.3 NORTH AMERICA: PRECISION DIAGNOSTICS MARKET, BY TYPE AND COUNTRY, 2023
- 4.4 PRECISION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029
- 4.5 PRECISION DIAGNOSTICS MARKET, BY END USER, 2023
- 4.6 NORTH AMERICA: PRECISION MEDICINE MARKET, BY PRODUCT AND COUNTRY, 2023
- 4.7 PRECISION MEDICINE MARKET, BY INDICATION, 2024 VS. 2029
- 4.8 PRECISION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.9 PRECISION MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing collaborations between pharmaceutical and diagnostic companies
- 5.2.1.2 Rise in direct-to-consumer testing
- 5.2.1.3 Growing integration of artificial intelligence and machine learning
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of precision healthcare
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Expanding applications of precision healthcare
- 5.2.3.2 Growing adoption of wearable devices
- 5.2.4 CHALLENGES
- 5.2.4.1 Complex regulatory approval landscape
- 5.2.4.2 Big data management and integration issues
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 5.4.2 AVERAGE SELLING PRICE TREND OF PRECISION MEDICINE PRODUCTS, BY KEY PLAYER
- 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
- 5.5 VALUE CHAIN ANALYSIS
- 5.5.1 PRECISION DIAGNOSTICS MARKET
- 5.5.2 PRECISION MEDICINE MARKET
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.6.1 PRECISION DIAGNOSTICS MARKET
- 5.6.2 PRECISION MEDICINE MARKET
- 5.7 ECOSYSTEM ANALYSIS
- 5.8 PIPELINE ANALYSIS
- 5.9 DIAGNOSTIC PRODUCT ANALYSIS
- 5.10 INVESTMENT/FUNDING ACTIVITY
- 5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
- 5.11.1.1 Next-generation sequencing
- 5.11.1.2 Immunohistochemistry
- 5.11.1.3 Liquid biopsy
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
- 5.11.2.1 Single-cell analysis
- 5.11.2.2 AI and ML integration
- 5.11.3 ADJACENT TECHNOLOGIES
- 5.11.3.1 Theranostics
- 5.11.3.2 Imaging technologies
- 5.12 PATENT ANALYSIS
- 5.13 TRADE ANALYSIS
- 5.13.1 IMPORT DATA
- 5.13.2 EXPORT DATA
- 5.14 KEY CONFERENCES AND EVENTS, 2025-2026
- 5.15 REGULATORY LANDSCAPE
- 5.15.1 REGULATORY ANALYSIS
- 5.15.1.1 North America
- 5.15.1.2 Europe
- 5.15.1.3 Asia Pacific
- 5.15.1.4 Rest of the World
- 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.16 PORTER'S FIVE FORCES ANALYSIS
- 5.16.1 PRECISION DIAGNOSTICS MARKET
- 5.16.1.1 Threat of new entrants
- 5.16.1.2 Threat of substitutes
- 5.16.1.3 Bargaining power of buyers
- 5.16.1.4 Bargaining power of suppliers
- 5.16.1.5 Intensity of competitive rivalry
- 5.16.2 PRECISION MEDICINE MARKET
- 5.16.2.1 Threat of new entrants
- 5.16.2.2 Threat of substitutes
- 5.16.2.3 Bargaining power of buyers
- 5.16.2.4 Bargaining power of suppliers
- 5.16.2.5 Intensity of competitive rivalry
- 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.17.2 BUYING CRITERIA
- 5.18 IMPACT OF AI/GEN AI ON PRECISION DIAGNOSTICS AND MEDICINE MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 MARKET POTENTIAL OF PRECISION DIAGNOSTICS AND MEDICINES
- 5.18.3 AI USE CASES
- 5.18.4 KEY COMPANIES IMPLEMENTING AI
- 5.18.5 FUTURE OF GENERATIVE AI ON PRECISION DIAGNOSTICS AND MEDICINE ECOSYSTEM
6 PRECISION DIAGNOSTICS MARKET, BY TYPE
- 6.1 INTRODUCTION
- 6.2 GENETIC TESTING
- 6.2.1 NEED TO DETECT HEREDITARY AND RARE DISEASES TO STIMULATE GROWTH
- 6.3 DTC TESTING
- 6.3.1 INCREASED AWARENESS ABOUT PERSONALIZED HEALTH TO ENCOURAGE GROWTH
- 6.4 OTHER TYPES
7 PRECISION DIAGNOSTICS MARKET, BY INDICATION
- 7.1 INTRODUCTION
- 7.2 ONCOLOGY
- 7.2.1 RISING CANCER CASES TO ACCELERATE GROWTH
- 7.3 NEUROLOGY
- 7.3.1 INCREASING DEVELOPMENT OF PRECISION DIAGNOSTIC TESTS FOR NEUROLOGICAL DISEASES TO FUEL MARKET
- 7.4 IMMUNOLOGY
- 7.4.1 GROWING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIAGNOSTIC TOOLS TO DRIVE MARKET
- 7.5 OTHER DIAGNOSTIC INDICATIONS
8 PRECISION DIAGNOSTICS MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.2 CLINICAL LABORATORIES
- 8.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO FACILITATE GROWTH
- 8.3 HOSPITALS
- 8.3.1 GROWING COLLABORATIONS AMONG DIAGNOSTIC MANUFACTURING COMPANIES TO DRIVE MARKET
- 8.4 HOME CARE SETTINGS
- 8.4.1 INCREASING DEMAND FOR AT-HOME DIAGNOSTIC TESTS TO SPUR GROWTH
9 PRECISION MEDICINE MARKET, BY PRODUCT
- 9.1 INTRODUCTION
- 9.2 MONOCLONAL ANTIBODIES
- 9.2.1 RISING ADOPTION OF ONCOLOGY AND AUTOIMMUNE THERAPIES TO SUPPORT GROWTH
- 9.3 INHIBITOR DRUGS
- 9.3.1 INCREASING FDA APPROVALS FOR NOVEL INHIBITORS TO CONTRIBUTE TO GROWTH
- 9.4 CELL & GENE THERAPIES
- 9.4.1 GROWING INVESTMENTS IN GENETIC DISORDER RESEARCH TO FUEL MARKET
- 9.5 ANTIVIRAL & ANTI-RETROVIRAL DRUGS
- 9.5.1 NEED TO TARGET VIRAL INFECTIONS AND PREVENT VIRUS SPREAD TO FACILITATE GROWTH
- 9.6 OTHER PRODUCTS
10 PRECISION MEDICINE MARKET, BY INDICATION
- 10.1 INTRODUCTION
- 10.2 ONCOLOGY
- 10.2.1 GROWING EMPHASIS ON DEVELOPING PRECISION CANCER THERAPIES TO BOOST MARKET
- 10.3 RARE DISEASES
- 10.3.1 SHIFTING FOCUS ON TARGETED TREATMENT TO FAVOR GROWTH
- 10.4 INFECTIOUS DISEASES
- 10.4.1 NEED TO ENHANCE EFFICACY OF TREATMENTS TO DRIVE MARKET
- 10.5 HEMATOLOGICAL DISORDERS
- 10.5.1 INCREASING RESEARCH ON DEVELOPING PERSONALIZED THERAPIES TO AUGMENT GROWTH
- 10.6 OTHER MEDICINE INDICATIONS
11 PRECISION MEDICINE MARKET, BY END USER
- 11.1 INTRODUCTION
- 11.2 HOSPITALS & CLINICS
- 11.2.1 GROWING FOCUS ON PRECISION THERAPIES TO FUEL MARKET
- 11.3 HOME CARE SETTINGS
- 11.3.1 INCREASING PREFERENCE FOR SELF-ADMINISTRATION TECHNIQUES TO EXPEDITE GROWTH
12 PRECISION DIAGNOSTICS AND MEDICINE MARKET, BY REGION
- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 12.2.2 US
- 12.2.2.1 Well-established infrastructure and availability of advanced treatments to augment growth
- 12.2.3 CANADA
- 12.2.3.1 Growing cancer burden to support growth
- 12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
- 12.3.2.1 Growing collaborations between research institutions and healthcare providers to boost market
- 12.3.3 UK
- 12.3.3.1 Favorable government support to expedite growth
- 12.3.4 FRANCE
- 12.3.4.1 Growing preference for personalized medicine to fuel market
- 12.3.5 ITALY
- 12.3.5.1 Rise in genomics research and diagnostic testing to foster growth.
- 12.3.6 SPAIN
- 12.3.6.1 Robust network of healthcare systems, research centers, and universities to facilitate growth
- 12.3.7 REST OF EUROPE
- 12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
- 12.4.2.1 Growing regulatory approvals for precision medicines to boost market
- 12.4.3 JAPAN
- 12.4.3.1 Increasing availability of health insurance to encourage growth
- 12.4.4 INDIA
- 12.4.4.1 Rising burden of chronic diseases to promote growth
- 12.4.5 AUSTRALIA
- 12.4.5.1 Booming research & development investments to spur growth
- 12.4.6 REST OF ASIA PACIFIC
- 12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
- 12.5.2.1 Growing incorporation of genomic medicine into public healthcare to drive market
- 12.5.3 MEXICO
- 12.5.3.1 Booming biopharmaceutical sector to contribute to growth
- 12.5.4 REST OF LATIN AMERICA
- 12.6 MIDDLE EAST & AFRICA
- 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
- 13.1 OVERVIEW
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024
- 13.2.1 PRECISION DIAGNOSTICS MARKET
- 13.2.2 PRECISION MEDICINE MARKET
- 13.3 REVENUE ANALYSIS, 2021-2023
- 13.3.1 PRECISION DIAGNOSTICS MARKET
- 13.3.2 PRECISION MEDICINE MARKET
- 13.4 MARKET SHARE ANALYSIS, 2023
- 13.4.1 PRECISION DIAGNOSTICS MARKET
- 13.4.2 PRECISION MEDICINE MARKET
- 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 13.5.1 PRECISION DIAGNOSTICS MARKET
- 13.5.1.1 Stars
- 13.5.1.2 Emerging leaders
- 13.5.1.3 Pervasive players
- 13.5.1.4 Participants
- 13.5.1.5 Company footprint: Key players, 2023
- 13.5.1.5.1 Company footprint
- 13.5.1.5.2 Region footprint
- 13.5.1.5.3 Type footprint
- 13.5.1.5.4 Indication footprint
- 13.5.2 PRECISION MEDICINE MARKET
- 13.5.2.1 Stars
- 13.5.2.2 Emerging leaders
- 13.5.2.3 Pervasive players
- 13.5.2.4 Participants
- 13.5.2.5 Company footprint: Key players, 2023
- 13.5.2.5.1 Company footprint
- 13.5.2.5.2 Region footprint
- 13.5.2.5.3 Product footprint
- 13.5.2.5.4 Indication footprint
- 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 13.6.1 PRECISION DIAGNOSTICS MARKET
- 13.6.1.1 Progressive companies
- 13.6.1.2 Responsive companies
- 13.6.1.3 Dynamic companies
- 13.6.1.4 Starting blocks
- 13.6.1.5 Competitive benchmarking
- 13.6.1.5.1 Detailed list of key startups/SMES
- 13.6.1.5.2 Competitive benchmarking of startups/SMEs
- 13.6.2 PRECISION MEDICINE MARKET
- 13.6.2.1 Progressive companies
- 13.6.2.2 Responsive companies
- 13.6.2.3 Dynamic companies
- 13.6.2.4 Starting blocks
- 13.6.2.5 Competitive benchmarking
- 13.6.2.5.1 Detailed list of key startups/SMES
- 13.6.2.5.2 Competitive benchmarking of startups/SMEs
- 13.7 COMPANY VALUATION AND FINANCIAL METRICS
- 13.7.1 PRECISION DIAGNOSTICS MARKET
- 13.7.2 PRECISION MEDICINE MARKET
- 13.8 BRAND/PRODUCT COMPARISON
- 13.9 PRECISION DIAGNOSTICS MARKET: COMPETITIVE SCENARIO
- 13.9.1 PRODUCT LAUNCHES AND APPROVALS
- 13.9.2 DEALS
- 13.9.3 EXPANSIONS
- 13.10 PRECISION MEDICINE MARKET: COMPETITIVE SCENARIO
- 13.10.1 PRODUCT LAUNCHES AND APPROVALS
- 13.10.2 DEALS
- 13.10.3 EXPANSIONS
14 COMPANY PROFILES
- 14.1 KEY PLAYERS
- 14.1.1 F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
- 14.1.1.1 Business overview
- 14.1.1.2 Products offered
- 14.1.1.3 Recent developments
- 14.1.1.3.1 Product launches and approvals
- 14.1.1.3.2 Deals
- 14.1.1.4 MnM view
- 14.1.1.4.1 Key strengths
- 14.1.1.4.2 Strategic choices
- 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 ABBOTT
- 14.1.2.1 Business overview
- 14.1.2.2 Products offered
- 14.1.2.3 Recent developments
- 14.1.2.4 MnM view
- 14.1.2.4.1 Key strengths
- 14.1.2.4.2 Strategic choices
- 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 AGILENT TECHNOLOGIES, INC.
- 14.1.3.1 Business overview
- 14.1.3.2 Products offered
- 14.1.3.3 Recent developments
- 14.1.3.3.1 Product launches and approvals
- 14.1.3.3.2 Deals
- 14.1.3.3.3 Expansions
- 14.1.3.4 MnM view
- 14.1.3.4.1 Key strengths
- 14.1.3.4.2 Strategic choices
- 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 GUARDANT HEALTH
- 14.1.4.1 Business overview
- 14.1.4.2 Products offered
- 14.1.4.3 Recent developments
- 14.1.4.3.1 Product launches and approvals
- 14.1.4.3.2 Deals
- 14.1.4.4 MnM view
- 14.1.4.4.1 Key strengths
- 14.1.4.4.2 Strategic choices
- 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 EXACT SCIENCES CORPORATION
- 14.1.5.1 Business overview
- 14.1.5.2 Products offered
- 14.1.5.3 Recent developments
- 14.1.5.3.1 Product launches and approvals
- 14.1.5.3.2 Deals
- 14.1.5.4 MnM view
- 14.1.5.4.1 Key strengths
- 14.1.5.4.2 Strategic choices
- 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 QIAGEN
- 14.1.6.1 Business overview
- 14.1.6.2 Products offered
- 14.1.6.3 Recent developments
- 14.1.6.3.1 Product launches and approvals
- 14.1.6.3.2 Deals
- 14.1.7 MYRIAD GENETICS, INC.
- 14.1.7.1 Business overview
- 14.1.7.2 Products offered
- 14.1.7.3 Recent developments
- 14.1.7.3.1 Product launches and approvals
- 14.1.7.3.2 Deals
- 14.1.7.3.3 Other developments
- 14.1.8 NATERA, INC.
- 14.1.8.1 Business overview
- 14.1.8.2 Products offered
- 14.1.8.3 Recent developments
- 14.1.8.3.1 Product launches and approvals
- 14.1.8.3.2 Deals
- 14.1.9 ILLUMINA, INC.
- 14.1.9.1 Business overview
- 14.1.9.2 Products offered
- 14.1.9.3 Recent developments
- 14.1.9.3.1 Product launches and approvals
- 14.1.9.3.2 Deals
- 14.1.10 THERMO FISHER SCIENTIFIC INC.
- 14.1.10.1 Business overview
- 14.1.10.2 Products offered
- 14.1.10.3 Recent developments
- 14.1.10.3.1 Product launches and approvals
- 14.1.10.3.2 Deals
- 14.1.11 DANAHER
- 14.1.11.1 Business overview
- 14.1.11.2 Products offered
- 14.1.11.3 Recent developments
- 14.1.11.3.1 Product launches and approvals
- 14.1.11.3.2 Deals
- 14.1.12 23ANDME, INC.
- 14.1.12.1 Business overview
- 14.1.12.2 Products offered
- 14.1.12.3 Recent developments
- 14.1.13 MERCK & CO., INC.
- 14.1.13.1 Business overview
- 14.1.13.2 Products offered
- 14.1.13.3 Recent developments
- 14.1.13.3.1 Product launches and approvals
- 14.1.13.3.2 Deals
- 14.1.14 GILEAD SCIENCES, INC.
- 14.1.14.1 Business overview
- 14.1.14.2 Products offered
- 14.1.14.3 Recent developments
- 14.1.14.3.1 Product launches and approvals
- 14.1.14.3.2 Deals
- 14.1.15 F. HOFFMANN-LA ROCHE LTD (MEDICINE)
- 14.1.15.1 Business overview
- 14.1.15.2 Products offered
- 14.1.15.3 Recent developments
- 14.1.15.3.1 Product launches and approvals
- 14.1.16 BRISTOL-MYERS SQUIBB COMPANY
- 14.1.16.1 Business overview
- 14.1.16.2 Products offered
- 14.1.16.3 Recent developments
- 14.1.16.3.1 Product launches and approvals
- 14.1.16.3.2 Deals
- 14.1.17 NOVARTIS AG
- 14.1.17.1 Business overview
- 14.1.17.2 Products offered
- 14.1.17.3 Recent developments
- 14.1.17.3.1 Product launches and approvals
- 14.1.17.3.2 Deals
- 14.1.18 ASTRAZENECA
- 14.1.18.1 Business overview
- 14.1.18.2 Products offered
- 14.1.18.3 Recent developments
- 14.1.18.3.1 Product launches and approvals
- 14.1.18.3.2 Deals
- 14.1.19 ABBVIE INC.
- 14.1.19.1 Business overview
- 14.1.19.2 Products offered
- 14.1.19.3 Recent developments
- 14.1.19.3.1 Product launches and approvals
- 14.1.19.3.2 Deals
- 14.1.19.3.3 Expansions
- 14.1.20 LILLY
- 14.1.20.1 Business overview
- 14.1.20.2 Products offered
- 14.1.20.3 Recent developments
- 14.1.20.3.1 Product launches and approvals
- 14.1.20.3.2 Deals
- 14.1.21 PFIZER INC.
- 14.1.21.1 Business overview
- 14.1.21.2 Products offered
- 14.1.21.3 Recent developments
- 14.1.21.3.1 Product launches and approvals
- 14.1.21.3.2 Deals
- 14.1.22 SAREPTA THERAPEUTICS, INC.
- 14.1.22.1 Business overview
- 14.1.22.2 Products offered
- 14.1.22.3 Recent developments
- 14.1.22.3.1 Product launches and approvals
- 14.1.22.3.2 Deals
- 14.1.23 VERTEX PHARMACEUTICALS INCORPORATED
- 14.1.23.1 Business overview
- 14.1.23.2 Products offered
- 14.1.23.3 Recent developments
- 14.1.23.3.1 Product launches and approvals
- 14.1.23.3.2 Deals
- 14.1.24 GSK PLC.
- 14.1.24.1 Business overview
- 14.1.24.2 Products offered
- 14.1.24.3 Recent developments
- 14.1.24.3.1 Product launches and approvals
- 14.1.24.3.2 Deals
- 14.2 OTHER PLAYERS
- 14.2.1 SANOFI
- 14.2.2 JOHNSON & JOHNSON SERVICES, INC.
- 14.2.3 AMGEN INC.
- 14.2.4 MERCK KGAA
- 14.2.5 ALNYLAM PHARMACEUTICALS, INC.
- 14.2.6 INCYTE
- 14.2.7 ARUP LABORATORIES
- 14.2.8 DEVYSER
- 14.2.9 DIASORIN S.P.A.
- 14.2.10 TEMPUS
- 14.2.11 PILLAR BIOSCIENCES INC.
- 14.2.12 INVIVOSCRIBE, INC.
- 14.2.13 NEUROCODE
- 14.2.14 C2N DIAGNOSTICS
- 14.2.15 TRINITY BIOTECH
- 14.2.16 AMOY DIAGNOSTICS CO., LTD.
15 APPENDIX
- 15.1 DISCUSSION GUIDE
- 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 15.3 CUSTOMIZATION OPTIONS
- 15.4 RELATED REPORTS
- 15.5 AUTHOR DETAILS
